Perkins Coie’s ECVC Practice Advises Adcentrx in $38M Series A+ Funding Round

AUSTIN (May 19, 2023)—Perkins Coie is pleased to have advised Adcentrx Therapeutics in a $38M Series A+ financing led by Eight Roads Ventures. For more information, please see Adcentrx's press release here. 

Adcentrx is a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases. Adcentrx plans to use the proceeds from the financing to advance its proprietary ADC therapeutic pipeline into the clinic.

The Perkins Coie advisory team was headed by Emerging Companies & Venture Capital (ECVC) partner Valeska Pederson Hintz and included associates Sam Kim and Kaina Pengilly. Additional support was provided by different practices groups in Perkins Coie offices in the U.S. and China, including tax partner Bryan Smith, tax counsel Eric Ashcroft, and regulatory partners Jamie Schafer.

From incorporation to exit, Perkins Coie helps clients build great companies. Lawyers in our Emerging Companies & Venture Capital practice span the country supporting the most innovative entrepreneurs and investors in Palo Alto, San Francisco, Los Angeles, Seattle, Austin, Portland, and New York, as well as Chicago and Boise. Our ECVC lawyers have managed thousands of venture capital and private equity financings, from pre-seed to growth stage, and provide end-to-end legal and business counseling to the leading-edge companies of tomorrow in industries from SaaS to life sciences and healthcare to Web3 and everything in between.